NeuroPace(NPCE) - 2024 Q4 - Annual Results

Financial Performance - NeuroPace reported preliminary unaudited revenue for Q4 2024 and the year ended December 31, 2024, but specific figures were not disclosed[5]. - The company had cash and short-term investments as of December 31, 2024, but exact amounts were not provided in the report[5]. Corporate Governance - The Board of Directors increased its size from seven to eight members, appointing Scott Huennekens as a new director effective January 6, 2025[7]. - Huennekens was granted a stock option to purchase 15,507 shares at an exercise price of $11.93 per share, with a vesting schedule over three years[9]. Clinical Trials - NeuroPace's NAUTILUS pivotal trial is on track to complete the one-year follow-up of subjects by March 2025, with data analysis starting in Q2 2025[11]. - The trial aims to evaluate the safety and effectiveness of the RNS System for patients aged 12 and older with drug-resistant idiopathic generalized epilepsy[11].